Sedana Medical AB (publ) (SEDANA.ST)
SEK 16.0
(0.38%)
SEK 16.0
(0.38%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -226.87 Million SEK | 62.12% |
| 2022 | -598.99 Million SEK | 27.6% |
| 2021 | -827.3 Million SEK | -124.89% |
| 2020 | -367.88 Million SEK | 20.38% |
| 2019 | -462.02 Million SEK | -189.94% |
| 2018 | -159.35 Million SEK | -86.77% |
| 2017 | -85.31 Million SEK | -2425.7% |
| 2016 | -3.37 Million SEK | -233.1% |
| 2015 | 2.53 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -296.32 Million SEK | 16.91% |
| 2024 Q1 | -356.63 Million SEK | -57.19% |
| 2024 Q3 | -222.65 Million SEK | 26.04% |
| 2023 Q3 | -285.47 Million SEK | -58.38% |
| 2023 Q4 | -226.87 Million SEK | 20.53% |
| 2023 FY | -226.87 Million SEK | 62.12% |
| 2023 Q1 | -243.57 Million SEK | 59.34% |
| 2023 Q2 | -180.24 Million SEK | 26.0% |
| 2022 FY | -598.99 Million SEK | 27.6% |
| 2022 Q2 | -713 Million SEK | 7.25% |
| 2022 Q3 | -666.83 Million SEK | 6.48% |
| 2022 Q4 | -598.99 Million SEK | 10.17% |
| 2022 Q1 | -768.75 Million SEK | 7.08% |
| 2021 Q1 | -335.04 Million SEK | 8.93% |
| 2021 Q2 | -298.59 Million SEK | 10.88% |
| 2021 FY | -827.3 Million SEK | -124.89% |
| 2021 Q4 | -827.3 Million SEK | -227.68% |
| 2021 Q3 | -252.47 Million SEK | 15.44% |
| 2020 Q1 | -442.55 Million SEK | 4.21% |
| 2020 FY | -367.88 Million SEK | 20.38% |
| 2020 Q4 | -367.88 Million SEK | 9.47% |
| 2020 Q3 | -406.34 Million SEK | 6.27% |
| 2020 Q2 | -433.53 Million SEK | 2.04% |
| 2019 Q4 | -462.02 Million SEK | -278.23% |
| 2019 FY | -462.02 Million SEK | -189.94% |
| 2019 Q1 | -149.84 Million SEK | 4.6% |
| 2019 Q2 | -137.31 Million SEK | 8.36% |
| 2019 Q3 | -122.15 Million SEK | 11.04% |
| 2018 Q4 | -157.07 Million SEK | 10.32% |
| 2018 FY | -159.35 Million SEK | -86.77% |
| 2018 Q1 | -79.15 Million SEK | 7.22% |
| 2018 Q2 | -181.59 Million SEK | -129.41% |
| 2018 Q3 | -175.15 Million SEK | 3.55% |
| 2017 Q3 | -89.61 Million SEK | 4.8% |
| 2017 Q2 | -94.13 Million SEK | -5150.34% |
| 2017 FY | -85.31 Million SEK | -2425.7% |
| 2017 Q4 | -85.31 Million SEK | 4.8% |
| 2017 Q1 | -1.79 Million SEK | 46.92% |
| 2016 Q4 | -3.37 Million SEK | 0.0% |
| 2016 FY | -3.37 Million SEK | -233.1% |
| 2015 FY | 2.53 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | -545.464% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 118.492% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 118.492% |
| Arcoma AB | -1.12 Million SEK | -20012.943% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | 306.471% |
| BICO Group AB (publ) | 927.9 Million SEK | 124.45% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | 276.144% |
| CellaVision AB (publ) | -56.94 Million SEK | -298.43% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | -1424.998% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | -2583.245% |
| C-Rad AB (publ) | -127.6 Million SEK | -77.801% |
| Duearity AB (publ) | 10.23 Million SEK | 2317.515% |
| Dignitana AB (publ) | 13.07 Million SEK | 1834.909% |
| Episurf Medical AB (publ) | -52.7 Million SEK | -330.501% |
| Getinge AB (publ) | 5.4 Billion SEK | 104.195% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | -547.23% |
| Iconovo AB (publ) | -10.75 Million SEK | -2009.409% |
| Integrum AB (publ) | -10.47 Million SEK | -2065.544% |
| Luxbright AB (publ) | -13.83 Million SEK | -1540.037% |
| Mentice AB (publ) | -49.56 Million SEK | -357.739% |
| OssDsign AB (publ) | -162.78 Million SEK | -39.368% |
| Paxman AB (publ) | -11.41 Million SEK | -1888.204% |
| Promimic AB (publ) | -50.32 Million SEK | -350.836% |
| Qlife Holding AB (publ) | 19.07 Million SEK | 1289.691% |
| SciBase Holding AB (publ) | -27.32 Million SEK | -730.31% |
| ScandiDos AB (publ) | -1.53 Million SEK | -14718.681% |
| Sectra AB (publ) | -772.85 Million SEK | 70.645% |
| Senzime AB (publ) | -139.54 Million SEK | -62.586% |
| SpectraCure AB (publ) | -50.23 Million SEK | -351.634% |
| Stille AB | -178.5 Million SEK | -27.097% |
| Vitrolife AB (publ) | 1.22 Billion SEK | 118.475% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | -5.694% |